



## Formulary Addition Request Form

This form is used to request additions to the Stony Brook Hospital Drug Formulary. Additions may only be requested by **attending physicians** or through needs identified by the Pharmacy Department.

### I. Instructions

1. All portions of this form must be completed or it will be returned.
2. Submit completed forms, along with supporting documentation to the Director of Pharmacy Services at **mailbox 7007**
3. Forms must be submitted at least four weeks prior to a Pharmacy and Therapeutics Committee meeting (third Wednesday of the month) in order to be placed on the agenda of the next meeting and allow appropriate time for review.
4. The requestor(s) or physician designee should be available to appear before the Pharmacy and Therapeutics Committee when the drug is presented for approval.

**Form received in Pharmacy by:** \_\_\_\_\_ **Date:** \_\_\_\_\_

### II. Drug Information *(Click on gray area and begin typing. Gray shading will not appear on printed document)*

- Generic Name: \_\_\_\_\_ Trade name(s): \_\_\_\_\_
- Manufacturer(s): \_\_\_\_\_
- Indication(s): \_\_\_\_\_  
Mechanism of action: \_\_\_\_\_
- Usual dosage, frequency, and duration of therapy: \_\_\_\_\_  
Anticipated **monthly** frequency of use:  
Number of patients: \_\_\_\_\_ Inpatients:  Outpatients:  *(to put an x in box, click on box icon)*  
Expected cost per patient admission: \_\_\_\_\_  
Comparable drug(s) on Formulary: \_\_\_\_\_  
Situations in which this drug is more effective/superior to medications on Formulary.  
\_\_\_\_\_  
Which drug(s) could be deleted from the formulary?  
\_\_\_\_\_  
Special risks, cautions and restrictions in use:  
\_\_\_\_\_  
Special considerations related to patient safety ("look alike, sound alike"):  
\_\_\_\_\_  
Pertinent literature references (attached):  
\_\_\_\_\_
- Suggested criteria for use. *Please attach additional sheets if necessary.*  
A. Inclusion Criteria: \_\_\_\_\_  
Monitoring parameters *(Including adverse drug reactions/interactions that may occur and preventative and/or responsive management for each)*: \_\_\_\_\_

Outcome measures (markers to determine drug efficacy): \_\_\_\_\_

**III. Miscellaneous Information**

- Have you been an investigator in any research study involving the use of this drug? Yes No
- Within the last two years, have you served as an advisor, received honoraria and/or research funding from the company manufacturing or promoting this product. Yes No

If you answered "yes" to either of the above questions, please explain:

\_\_\_\_\_

Requested by: \_\_\_\_\_, MD      Date: \_\_\_\_\_

Printed Name; \_\_\_\_\_ Department/Division \_\_\_\_\_

Chair/Chief approval (signature): \_\_\_\_\_

(printed name) \_\_\_\_\_

---

**P&T Committee Recommendation**

Recommendation to add: Yes No      Date of Meeting: \_\_\_\_\_

Signature, P&T Committee Chair: \_\_\_\_\_, MD

---

—